The c-reactive protein testing market size has grown strongly in recent years. It will grow from $3.52 billion in 2025 to $3.7 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to increasing prevalence of inflammatory diseases, rising use of crp testing in clinical diagnostics, expansion of hospital laboratory infrastructure, growing awareness of early disease detection, availability of standardized assay kits.
The c-reactive protein testing market size is expected to see steady growth in the next few years. It will grow to $4.48 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing demand for point-of-care inflammatory testing, rising integration of automated diagnostics platforms, expansion of preventive healthcare screening, growing adoption of high-throughput laboratory systems, increasing focus on personalized medicine diagnostics. Major trends in the forecast period include increasing adoption of high-sensitivity crp assays, rising use of automated immunoassay systems, growing demand for rapid inflammation diagnostics, expansion of crp testing in cardiovascular risk assessment, enhanced focus on laboratory workflow automation.
The rise in cardiovascular disease (CVD) cases is expected to drive the growth of the C-reactive protein testing market. Cardiovascular diseases encompass heart conditions such as diseased vessels, structural issues, and blood clots. While the exact cause of CVD is not fully understood, several factors can increase the risk of developing it. One significant factor is behavioral risk, stemming from poor diet, insufficient physical activity, smoking, and alcohol consumption, which leads to the buildup of fatty deposits in the arteries (atherosclerosis) and heightens the risk of blood clots. These behavioral risks contribute to elevated blood pressure, glucose levels, blood lipids, weight gain, and obesity. As CVD cases rise, there is an increasing demand for C-reactive protein testing to diagnose or predict the likelihood of cardiovascular issues, similar to cholesterol testing. For example, in December 2023, the Institute for Health Metrics and Evaluation reported that global deaths from cardiovascular diseases reached 19.8 million in 2022, with ischemic heart disease accounting for 108.8 deaths per 100,000 people. High systolic blood pressure was the leading contributor to disability-adjusted life years (DALYs) associated with CVD, while dietary risks and air pollution emerged as significant behavioral and environmental factors exacerbating this global issue.
Major players in the C-Reactive Protein testing market are focusing on technological advancements such as high-sensitivity automated immunoassays for more accurate, rapid, and low-level CRP detection, supporting early cardiovascular risk assessment and real-time inflammation monitoring. High-sensitivity automated immunoassays use refined immunoturbidimetric or nephelometric techniques to detect CRP levels far below standard assays, enabling earlier intervention and improved prognostic evaluation. In January 2024, Siemens Healthineers, a Germany-based in vitro diagnostics company, launched the Atellica CH High Sensitivity C-Reactive Protein 2 (hCRP2) assay for its Atellica CH Analyzer. The system uses two ready-to-use reagent packs and measures light scattering caused by CRP-induced particle aggregation, providing rapid, quantitative results compatible with serum or plasma samples for timely clinical decision-making.
In July 2024, Roche, a Switzerland-based diagnostics company, acquired LumiraDx’s point-of-care platform for an undisclosed amount. Through this acquisition, Roche seeks to enhance its CRP testing capabilities by incorporating LumiraDx’s rapid, quantitative CRP assay into its diagnostics portfolio and expanding access to point-of-care immunoassays. LumiraDx is a UK-based company that offers a multi-assay point-of-care platform, including a microfluidic immunoassay for quantitative C-Reactive Protein testing.
Major companies operating in the c-reactive protein testing market are Thermo Fisher Scientific Inc., F Hoffmann-La Roche AG, Danaher Corporation, Quest Diagnostics Incorporated, Siemens AG, Abbott Laboratories, Aidian Oy, Boditech Med Inc., Horiba Ltd., Laboratory Corporation, Merck KGAA, Randox Laboratories Limited, Getein Biotech Inc., Bio-Rad Laboratories Inc., DiaSorin S.p.A., Eurofins Scientific SE, Inova Diagnostics Inc., Luminex Corporation, Sekisui Diagnostics LLC, Sysmex Corporation, Tosoh Corporation, Trinity Biotech Plc, WerfenLife Group LLC, ZEUS Scientific Inc., BioMérieux SA, Biomerica Inc., Gold Standard Diagnostics Corp., Immunodiagnostic Systems Holdings PLC, Nova Biomedical Corporation.
North America was the largest region in the c-reactive protein testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c-reactive protein testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the c-reactive protein testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the c-reactive protein testing market by increasing costs of imported reagents, assay kits, analyzers, and diagnostic instrumentation used across elisa, clia, and immunoturbidimetric platforms. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported testing systems, while Asia-Pacific faces cost pressures on reagent supply chains. These tariffs are raising operational costs and impacting test pricing. At the same time, they are encouraging local reagent manufacturing, regional analyzer assembly, and domestic diagnostic technology development.
The c-reactive protein testing market research report is one of a series of new reports that provides c-reactive protein testing market statistics, including c-reactive protein testing industry global market size, regional shares, competitors with a c-reactive protein testing market share, detailed c-reactive protein testing market segments, market trends and opportunities, and any further data you may need to thrive in the c-reactive protein testing industry. This c-reactive protein testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
C-reactive protein (CRP) testing is a diagnostic procedure that assesses the concentration of CRP in the bloodstream, a protein produced by the liver in response to inflammation. In cases of injury or infection, the body initiates inflammation as a protective mechanism. CRP testing is primarily employed to identify inflammation resulting from infections.
The primary assay methods utilized in the CRP testing market include enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and immunoturbidimetric assays. ELISA, for instance, is a technique employed to quantitatively measure human CRP levels in serum, aiding in the monitoring of conditions such as rheumatic fever and inflammatory processes. ELISA serves as a biological assay focusing on the measurement of antibodies, antigens, proteins, and glycoproteins. CRP testing is widely applied in clinical settings, hospitals, and diagnostic laboratories, contributing to the diagnosis and monitoring of various conditions such as diabetes, rheumatoid arthritis, cardiovascular diseases, inflammatory bowel disease, cancer, and others.
The c-reactive protein testing market includes revenues earned by entities by devices and reagents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The c-reactive protein testing market size is expected to see steady growth in the next few years. It will grow to $4.48 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing demand for point-of-care inflammatory testing, rising integration of automated diagnostics platforms, expansion of preventive healthcare screening, growing adoption of high-throughput laboratory systems, increasing focus on personalized medicine diagnostics. Major trends in the forecast period include increasing adoption of high-sensitivity crp assays, rising use of automated immunoassay systems, growing demand for rapid inflammation diagnostics, expansion of crp testing in cardiovascular risk assessment, enhanced focus on laboratory workflow automation.
The rise in cardiovascular disease (CVD) cases is expected to drive the growth of the C-reactive protein testing market. Cardiovascular diseases encompass heart conditions such as diseased vessels, structural issues, and blood clots. While the exact cause of CVD is not fully understood, several factors can increase the risk of developing it. One significant factor is behavioral risk, stemming from poor diet, insufficient physical activity, smoking, and alcohol consumption, which leads to the buildup of fatty deposits in the arteries (atherosclerosis) and heightens the risk of blood clots. These behavioral risks contribute to elevated blood pressure, glucose levels, blood lipids, weight gain, and obesity. As CVD cases rise, there is an increasing demand for C-reactive protein testing to diagnose or predict the likelihood of cardiovascular issues, similar to cholesterol testing. For example, in December 2023, the Institute for Health Metrics and Evaluation reported that global deaths from cardiovascular diseases reached 19.8 million in 2022, with ischemic heart disease accounting for 108.8 deaths per 100,000 people. High systolic blood pressure was the leading contributor to disability-adjusted life years (DALYs) associated with CVD, while dietary risks and air pollution emerged as significant behavioral and environmental factors exacerbating this global issue.
Major players in the C-Reactive Protein testing market are focusing on technological advancements such as high-sensitivity automated immunoassays for more accurate, rapid, and low-level CRP detection, supporting early cardiovascular risk assessment and real-time inflammation monitoring. High-sensitivity automated immunoassays use refined immunoturbidimetric or nephelometric techniques to detect CRP levels far below standard assays, enabling earlier intervention and improved prognostic evaluation. In January 2024, Siemens Healthineers, a Germany-based in vitro diagnostics company, launched the Atellica CH High Sensitivity C-Reactive Protein 2 (hCRP2) assay for its Atellica CH Analyzer. The system uses two ready-to-use reagent packs and measures light scattering caused by CRP-induced particle aggregation, providing rapid, quantitative results compatible with serum or plasma samples for timely clinical decision-making.
In July 2024, Roche, a Switzerland-based diagnostics company, acquired LumiraDx’s point-of-care platform for an undisclosed amount. Through this acquisition, Roche seeks to enhance its CRP testing capabilities by incorporating LumiraDx’s rapid, quantitative CRP assay into its diagnostics portfolio and expanding access to point-of-care immunoassays. LumiraDx is a UK-based company that offers a multi-assay point-of-care platform, including a microfluidic immunoassay for quantitative C-Reactive Protein testing.
Major companies operating in the c-reactive protein testing market are Thermo Fisher Scientific Inc., F Hoffmann-La Roche AG, Danaher Corporation, Quest Diagnostics Incorporated, Siemens AG, Abbott Laboratories, Aidian Oy, Boditech Med Inc., Horiba Ltd., Laboratory Corporation, Merck KGAA, Randox Laboratories Limited, Getein Biotech Inc., Bio-Rad Laboratories Inc., DiaSorin S.p.A., Eurofins Scientific SE, Inova Diagnostics Inc., Luminex Corporation, Sekisui Diagnostics LLC, Sysmex Corporation, Tosoh Corporation, Trinity Biotech Plc, WerfenLife Group LLC, ZEUS Scientific Inc., BioMérieux SA, Biomerica Inc., Gold Standard Diagnostics Corp., Immunodiagnostic Systems Holdings PLC, Nova Biomedical Corporation.
North America was the largest region in the c-reactive protein testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c-reactive protein testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the c-reactive protein testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the c-reactive protein testing market by increasing costs of imported reagents, assay kits, analyzers, and diagnostic instrumentation used across elisa, clia, and immunoturbidimetric platforms. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported testing systems, while Asia-Pacific faces cost pressures on reagent supply chains. These tariffs are raising operational costs and impacting test pricing. At the same time, they are encouraging local reagent manufacturing, regional analyzer assembly, and domestic diagnostic technology development.
The c-reactive protein testing market research report is one of a series of new reports that provides c-reactive protein testing market statistics, including c-reactive protein testing industry global market size, regional shares, competitors with a c-reactive protein testing market share, detailed c-reactive protein testing market segments, market trends and opportunities, and any further data you may need to thrive in the c-reactive protein testing industry. This c-reactive protein testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
C-reactive protein (CRP) testing is a diagnostic procedure that assesses the concentration of CRP in the bloodstream, a protein produced by the liver in response to inflammation. In cases of injury or infection, the body initiates inflammation as a protective mechanism. CRP testing is primarily employed to identify inflammation resulting from infections.
The primary assay methods utilized in the CRP testing market include enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and immunoturbidimetric assays. ELISA, for instance, is a technique employed to quantitatively measure human CRP levels in serum, aiding in the monitoring of conditions such as rheumatic fever and inflammatory processes. ELISA serves as a biological assay focusing on the measurement of antibodies, antigens, proteins, and glycoproteins. CRP testing is widely applied in clinical settings, hospitals, and diagnostic laboratories, contributing to the diagnosis and monitoring of various conditions such as diabetes, rheumatoid arthritis, cardiovascular diseases, inflammatory bowel disease, cancer, and others.
The c-reactive protein testing market includes revenues earned by entities by devices and reagents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. C-Reactive Protein Testing Market Characteristics
3. C-Reactive Protein Testing Market Supply Chain Analysis
4. Global C-Reactive Protein Testing Market Trends and Strategies
5. C-Reactive Protein Testing Market Analysis of End Use Industries
7. Global C-Reactive Protein Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global C-Reactive Protein Testing Total Addressable Market (TAM) Analysis for the Market
9. C-Reactive Protein Testing Market Segmentation
10. C-Reactive Protein Testing Market Regional and Country Analysis
11. Asia-Pacific C-Reactive Protein Testing Market
12. China C-Reactive Protein Testing Market
13. India C-Reactive Protein Testing Market
14. Japan C-Reactive Protein Testing Market
15. Australia C-Reactive Protein Testing Market
16. Indonesia C-Reactive Protein Testing Market
17. South Korea C-Reactive Protein Testing Market
18. Taiwan C-Reactive Protein Testing Market
19. South East Asia C-Reactive Protein Testing Market
20. Western Europe C-Reactive Protein Testing Market
21. UK C-Reactive Protein Testing Market
22. Germany C-Reactive Protein Testing Market
23. France C-Reactive Protein Testing Market
24. Italy C-Reactive Protein Testing Market
25. Spain C-Reactive Protein Testing Market
26. Eastern Europe C-Reactive Protein Testing Market
27. Russia C-Reactive Protein Testing Market
28. North America C-Reactive Protein Testing Market
29. USA C-Reactive Protein Testing Market
30. Canada C-Reactive Protein Testing Market
31. South America C-Reactive Protein Testing Market
32. Brazil C-Reactive Protein Testing Market
33. Middle East C-Reactive Protein Testing Market
34. Africa C-Reactive Protein Testing Market
36. C-Reactive Protein Testing Market Competitive Landscape and Company Profiles
37. C-Reactive Protein Testing Market Other Major and Innovative Companies
40. C-Reactive Protein Testing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
C-Reactive Protein Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses c-reactive protein testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for c-reactive protein testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The c-reactive protein testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Assay Type: Enzyme-Linked Immunosorbent Assay (ELISA); Chemiluminescence Immunoassay (CLIA); Immunoturbidimetric Assays2) By Application: Diabetes; Rheumatoid Arthritis; Cardiovascular Disease; Inflammatory Bowel Disease; Cancer; Other Applications
3) By End Use: Clinics; Hospitals; Diagnostic Laboratories
Subsegments:
1) By Enzyme-Linked Immunosorbent Assay (ELISA): Direct ELISA; Indirect ELISA; Sandwich ELISA2) By Chemiluminescence Immunoassay (CLIA): Luminometer-Based CLIA; Automated CLIA Systems
3) By Immunoturbidimetric Assays: Nephelometry-Based Immunoturbidimetric Assays; Latex Agglutination Immunoturbidimetric Assays
Companies Mentioned: Thermo Fisher Scientific Inc.; F Hoffmann-La Roche AG; Danaher Corporation; Quest Diagnostics Incorporated; Siemens AG; Abbott Laboratories; Aidian Oy; Boditech Med Inc.; Horiba Ltd.; Laboratory Corporation; Merck KGAA; Randox Laboratories Limited; Getein Biotech Inc.; Bio-Rad Laboratories Inc.; DiaSorin S.p.A.; Eurofins Scientific SE; Inova Diagnostics Inc.; Luminex Corporation; Sekisui Diagnostics LLC; Sysmex Corporation; Tosoh Corporation; Trinity Biotech Plc; WerfenLife Group LLC; ZEUS Scientific Inc.; BioMérieux SA; Biomerica Inc.; Gold Standard Diagnostics Corp.; Immunodiagnostic Systems Holdings PLC; Nova Biomedical Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this C-Reactive Protein Testing market report include:- Thermo Fisher Scientific Inc.
- F Hoffmann-La Roche AG
- Danaher Corporation
- Quest Diagnostics Incorporated
- Siemens AG
- Abbott Laboratories
- Aidian Oy
- Boditech Med Inc.
- Horiba Ltd.
- Laboratory Corporation
- Merck KGAA
- Randox Laboratories Limited
- Getein Biotech Inc.
- Bio-Rad Laboratories Inc.
- DiaSorin S.p.A.
- Eurofins Scientific SE
- Inova Diagnostics Inc.
- Luminex Corporation
- Sekisui Diagnostics LLC
- Sysmex Corporation
- Tosoh Corporation
- Trinity Biotech Plc
- WerfenLife Group LLC
- ZEUS Scientific Inc.
- BioMérieux SA
- Biomerica Inc.
- Gold Standard Diagnostics Corp.
- Immunodiagnostic Systems Holdings PLC
- Nova Biomedical Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.7 Billion |
| Forecasted Market Value ( USD | $ 4.48 Billion |
| Compound Annual Growth Rate | 4.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
